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Background: The World Health Organization alert for the H1N1 influenza pandemic led to the implementation of
certain measures regarding admission of patients with flu-like symptoms. All these instructions were adopted by
the Greek National Health System. The aim of this study was to retrospectively examine the characteristics of all
subjects admitted to the Unit of Infectious Diseases with symptoms indicating H1N1 infection, and to identify any
differences between H1N1 positive or negative patients. Patients from the ED (emergency department) with flu-like
symptoms (sore throat, cough, rhinorhea, or nasal congestion) and fever >37.5°C were admitted in the Unit of
Infectious diseases and gave pharyngeal or nasopharyngeal swabs. Swabs were tested with real-time reverse-
transcriptase-polymerase-chain-reaction (RT-PCR).
Findings: Patients were divided into two groups. Group A comprised 33 H1N1 positive patients and Group B
(control group) comprised of 27 H1N1 negative patients. The two groups did not differ in terms of patient age,
co-morbidities, length of hospitalization, temperature elevation, hypoxemia, as well as renal and liver function.
There were also no significant differences in severity on admission. C-reactive protein (CRP) (mean 12.8 vs. 5.74)
and white blood count (WBC) (mean 10.528 vs. 7.114) were significantly higher in group B than in group A upon
admission. Obesity was noted in 8 patients of Group A (mean 31.67) and 14 patients of Group B (mean 37.78).
Body mass index (BMI) was lower in H1N1 positive than in H1N1 negative patients (mean 31.67 vs. 37.78,
respectively; p = 0.009).
Conclusions: The majority of patients in both groups were young male adults. CRP, WBC and BMI were higher
among H1N1 negative patients. Finally, clinical course of patients in both groups was mild and uneventful.
Background
In June 2009, the World Health Organization signaled
that a novel H1N1 flu pandemic was underway [1-5].
T h eH 1 N 1v i r u si sat r i p l e - r e assortant influenza virus
containing genes from human, swine, and avian influ-
enza viruses. This is a case control study. Patients were
selected from the influenza special clinic (emergency flu
department) according to their attendance. Control
group were patients with flu symptoms and signs with
negative serological test. Most patients with H1N1 infec-
tion present flu-like symptoms with a benign course [6].
Patients with co-morbidities may have a serious clinical
presentation with hypoxemia. The main cause of death
is acute respiratory distress syndrome (ARDS) [7-10].
The first case of influenza A (H1N1) virus infection in
the area of Thrace, Greece was documented in the Uni-
versity Hospital of Alexandroupolis on 10
th August
2009. The purpose of this study was to investigate the
potential differences on admission between H1N1 posi-
tive and negative patients with flu-like symptoms. * Correspondence: pzarog@hotmail.com
1Unit of Infectious Diseases, University General Hospital of Alexandroupolis,
Greece
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T h eU n i v e r s i t yH o s p i t a lo fA l e x a n d r o u p o l i si sar e p o r t
center of the H1N1 virus for the region of Thrace in
Greece. The hospital consists of more than fifty depart-
ments, one of which is the Unit of Infectious Diseases.
During the influenza epidemic a special department for
flu was established in which all patients with flu symp-
toms and/or signs were referred. Patients with positive
f l ut e s tw e r et r a n s f e r r e di na n8b e du n i tw i t hn e g a t i v e
pressure especially designed to quarantine and isolate
patients with airborne transmitted viral infections.
From 10th August until 31st December 2009, 33 cases
of confirmed H1N1 influenza A virus were hospitalized
and quarantined in the Unit of Infectious Diseases. All
patients with flu-like symptoms (sore throat, cough,
rhino rhea, or nasal congestion) and fever >37.5°C were
admitted in the Unit of Infectious diseases and gave
pharyngeal or nasopharyngeal swabs. The swabs were
tested with real-time reverse-transcriptase-polymerase-
chain-reaction (RT-PCR) as in previous reported studies
[11-13]. It should also be mentioned that although RT-
PCR is the most sensitive and specific test for the diag-
nosis of influenza virus infection, upper respiratory tract
specimens are not as specific (~80%) as lower respira-
tory tract specimens (~100%) [14]. All results were
given in a period of time from 8 to 48 hours, and all
patients remained under quarantine and isolation in
negative pressure chambers according to WHO guide-
lines [15]. Our department prefers to use the Pneumo-
n i aS e v e r i t yI n d e xi no r d e rt oe v a l u a t et h es e v e r i t yo f
the disease. However, this score was not different
between the two groups. The Pneumonia Score Index
was calculated for patients in both groups and the Class
range was between II-IV [16]. We repeated HINI test
7 days after admission and no patient negative in the
initial test became positive.
In total, 60 patients were admitted in a four month
period, of whom 33 were H1N1 positive (group A) and
27 negative (group B). The 33 H1N1 positive patients
remained under quarantine and isolation, while the 27
negative patients were moved to the Department of
Internal Medicine. Patients were monitored until dis-
charge, with symptoms and signs recorded daily. Return
to normal body temperature was defined as a tempera-
ture of less than 37°C for 1 day after withdrawal of anti-
pyretic treatment [17]. The criteria for discharge were
absence of hypoxemia, normal chest x-ray and tempera-
ture <37°C for 1 day without antipyretic treatment.
Upon admission procalcitonin (PCT) evaluation was
performed in 51 patients (25 group A/26 group B), for
nine patients this exam was not available due to lack in
reagents in our laboratory. Also urine antigen for Legio-
nella and Streptococcus pneumoniae was tested upon
admission in all patients but they were negative. Upon
admission sputum stain was given in 12/33 patients in
group A and 15/27 in group B. The rest of the patients
did not produce enough sputum quantity for staining or
did not cooperate in giving sputum. Finally blood cul-
tures were collected in 49/60 patients when the body
temperature exceeded 38°C, but no results came
positive.
Statistical Analysis
Continuous variables were summarized as mean (±SD)
or median (with interquartile ranges). For categorical
variables, the percentages of patients in each category
were calculated. Unpaired t test was used in normal dis-
tribution parameters comparing the mean values of the
parameters of the two groups. A p value of less than
0.05 was considered to indicate statistical significance.
Characteristics of the groups and clinical laboratory
parameters were compared between the two groups
(A, B). All analyses were carried out with the use of
SPSS statistical software package (SPSS version 17.01;
SPSS, Chicago, IL, USA).
Clinical Characteristics of Patients
The majority of H1N1 positive patients (group A) were
Caucasian male (23/33) with mean age 33.46 years and
H1N1 negative patients (group B) were Caucasian male
(17/27) with mean age 43.48 years. (Table 1.) Coexisting
conditions were present in 25/33 patients in group A and
18/27 patients in group B (asthma: 24.2% vs. 25.9%,
chronic obstructive disease: 6% vs. 0%, idiopathic pul-
monary fibrosis: 3% vs. 0%, lymphoma: 15% vs. 3.7%, dia-
betes: 9% vs. 18.5%, coronary heart disease: 18% vs.
18.5%) as in previous reported studies [12,18]. (Table 1.)
Only 2 patients in group A and 1 in group B had acute
asthma exacerbation and none of the females in this
study was pregnant. All female patients who were sexu-
ally active (8/33 group A) had negative pregnancy tests.
All patients were treated with oseltamivir regimen (mean
time 5.8 days in group A vs. 1.93 days in group B). In 7
patients of group A, additional treatment with azithromy-
cin/moxifloxacin or ceftriaxone was added at the time of
admission, due to local patchy shadowing on the chest
x-Rays and fever >37.5°C. In 7/33 patients of group A
and 10/27 of group B the second chest film was positive
for pneumonia infiltrates. The patient’s chest x-ray status
upon admission is presented in table 2.
In 6 out of 12 patients of group A from whom spu-
tum culture was received, a pathognomonic isolation
(>10
6 CFU) of bacteria was achieved (3 Streptococcus
pneumoniae species, 2 Mycoplasma species and 1 Mor-
axella catarrhalis). On the other hand from group B
only in 8 out of 15 patients a pathognomonic isolation
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3 Mycoplasma species).
In group B, all patients were treated with double anti-
biotic regimen amoxicillin-clavulanic acid+azithromycin
or ceftriaxone+moxifloxacin/ciprofloxacin (mean time of
hospitalization was 5.85 days). Empiric antibiotic treat-
ment was added upon admission based on elevated
values of CRP, WBC and chest x-ray findings and since
early antibiotic treatment prevents progression of the
disease and these markers are known to be elevated in
infection diseases [19-21]. Reiquelme et al [22] also
initiated early antiviral and antibiotic treatment in order
to prevent further progress and co-infection of the clini-
cal status. Patients in our study were discharged when
their chest radiograph became normal and their tem-
perature <37°C for 1 day. Seven patients of group A and
6p a t i e n t so fg r o u pBh a ds e v e r eh y p o x e m i au p o n
admission (PO2 ≤ 6 0m m H g )o nr o o ma i r .( T a b l e1 . )
Hypoxemia was defined as decreased partial pressure of
oxygen in blood ≤60 mmHg [23]. There was no difference
between the two groups for smoking (A: n = 7/33 vs. B:
n = 7/27). (Table 1.) Obesity was observed higher in
patients from group B (mean 37.78) and a small number
in group A (mean 31.67) (p value = 0.009). (Table 1.)
According to WHO global database on Body Mass Index
a patient is considered obese when BMI is ≥ 30 [24].
Laboratory Findings
Leucopenia grade 1 (≥2,500 to <4,000/mm
3)w a s
observed in 2/5 patients diagnosed with lymphoma in
group A. (Table 1.) In group B, only 1 patient had lym-
phoma and presented pneumonia. On admission, abnor-
mal liver function (elevated levels of serum liver enzymes
or bilirubin) was found in 4/33 patients in group A vs.
2/27 patients group B. (Table 1.) These patients were
under no treatment. Moreover, there was no platelet
abnormality in any patient of the two groups. C-reactive
protein (CRP normal laboratory values <0.50 mg/dL) and
white blood count (WBC) were elevated in group B in
comparison to group A (mean 12.8 vs. 5.74).
Among the white blood count (WBC) subgroups there
were no significant differences observed. The white
blood count (WBC) returned to normal in 9/33 patients
of group A and in 17/27 of group B between 6-12 days
of hospitalization. C-reactive protein (CRP) returned to
Table 1 Characteristics, underlying medical conditions and outcomes
Characteristic H1N1(+) Range (±SD) H1N1(-) Range (±SD) P Value
Age (years)
Mean 33.46 14-65 (14.7) 43.48 16-86 (22.7) 0.057
Male/Female 23/10 (69.69%/30.3%) 17/10(62.96%/37%) NS
Smoke 7/33 (21.2%) 7/27 (25.9%) NS
BMI
Mean 31.67 20-45 (9.15) 37.78 20-45 (8.0) 0.009
No,pts with obesity 18/33 (54.5%) 24/27 (88.8%)
Coexistinsting conditions
Asthma 8/33 (24.2%) 7/27 (25.9%) NS
COPD 2/33 (6%) 0 (0%) NS
IPF 1/33 (3%) 0 (0%) NS
Lymphoma 5/33 (15%) 1/27 (3.7%) NS
Diabetes 3/33 (9%) 5/27 (18.5%) NS
Coronary Heart Disease 6/33 (18%) 5/27 (18.5%) NS
Outcomes-days
Duration of fever
Mean 2.57 1-6 (1.0) 2.22 1-5 (1.0) 0.227
Days of Hospitalization
Mean 6.11 2-18 (3.2) 5.85 2-12 (2.6) 0.750
Days under oseltamivir regimen
Mean 5.8 5-18 (2.7) 1.93 1-5 (1.2) NS
Table 2 Radiographic findings in the two groups,
according to H1N1 status
H1N1(+) H1N1(-)
Abnormalities on chest radiograph
Local patchy shadowing 7/33 (21.2%) 10/27 (37.7%)
Ground-glass opacities 2/33 (6%) 7/27 (25.9%)
Interstitial abnormality 1/33 (3%) 0/27 (0%)
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Also in 4/33 patients in group A and 2/27 in group B
elevated levels of serum liver enzymes or bilirubin
returned to normal after 4-6 days. It should be
mentioned that none of the patients received medications
that affected their white blood count WBC (e.g. corticos-
teroids). (Table 3.)
None of the patients had acute renal failure and none
of the patients in the Unit of Infectious diseases had to
be intubated and admitted to the ICU in comparison to
other studies [7,25]. Also all patients were asked if they
had vaccination for H1N1, but none of them had been
vaccinated, even for seasonal influenza. There was no
d i f f e r e n c ei nm e a ns a t u r a t i o na m o n gt h et w og r o u p s .
(Table 3.) Only 2/33 patients in group A with hypoxe-
mia had to be hospitalized for 12 days and 18 days. The
one of these 2 patients was recently diagnosed with idio-
pathic pulmonary fibrosis, while the other had no co-
morbidities. No significant differences were observed for
mean temperature, saturation and partial O2 between
the two groups. (Table 3.)
Discussion and Conclusions
We described a case series of sixty patients who were
hospitalized in the Unit of Infectious diseases from 10
th
August to 31
st December 2009 with flu-like symptoms
and were tested with RT-PCR for H1N1 virus. Of these,
33 patients were positive for H1N1, while the remaining
27 were negative. The main differences between these
two groups and corresponding clinical messages are
summarized underneath.
In this case control study we included all patients with
influenza symptoms admitted to the emergency flu
department according to their attendance. Limitations of
the study include that our data represent the experience
of a single center, that procalcitonin test was given only
in 51/60 patients and also Erythrocyte Sedimentation
Rate (ESR) was sporadically collected during the follow
up of the patients and so was not evaluated. Bacterial
pneumoniae in association with influenza has been con-
sidered a important factor leading to poor patients out-
comes in prior pandemics [26]. Even though none of
t h eb l o o dc u l t u r e sw e r ep o s i t i v e ,w ew e r eu n a b l et o
evaluate the effect of bacterial co-infection on patient
outcomes, since blood cultures were obtained in only
17% of the study population (when fever ≥38°C) and
workup for atypical pathogens was not performed.
Although bacterial co-infection was not documented,
t h em a j o r i t yo ft h es t u d yp o p u l a t i o nw a st r e a t e dw i t h
antibiotics. Prior publications failed to demonstrate any
significant involvement of bacterial pathogens in hospi-
talized patients with 2009 H1N1 virus pneumonia
[3,27-29]. During the initial evaluation in 4/27 patients
of group B and 6/33 of group A an antibiotic treatment
was prescribed by a General Practitioner and none of
these patients had a sputum culture at that time.
Table 3 Clinical features of infection, according to H1N1 status: symptoms, signs and laboratory tests upon admission
H1N1(+) Range (±SD) H1N1(-) Range (±SD) P Value
Adverse events
Abnormal liver function 4/33 (12%) 2/27 (7.4%) NS
Nausea, Diarrhea 4.5% 1.5% NS
Vomiting 1.4% 0.5% NS
Hypoxemia 7/33 (21.2%) 6/27 (22.2%) NS
CRP
Mean 5.74 0.26-17.38 (4.75) 12.8 0.14-43.98 (11.56) 0.004
WBC
Mean 7.114 3.340-10.950 (2172.160) 10,528 2.660-23.050 (5506.19) 0.004
Fever
Mean 38.99 36.60-40 (0.79) 38.6 36.50-40.80 (1.01) 0.122
CR
Mean 0.9 0.5-1.30 (0.18) 0.85 0.20-1.60 (0.25) 0.392
UR
Mean 26.5 11-41 (7.9) 32.2 17-72 (11.8) 0.038
Spo2
Mean 95.3 89-99 (2.7) 95.2 89-100 (2.4) 0.809
PO2 (FiO221%)
Mean 77.54 54-113 (14.6) 74,22 56-108 (13.0) 0.381
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ples from all patients. We supposed that false negative
culture in pneumonia patients is mainly due to mixed
microbial flora or the natural colonization admixture of
the upper airway. The subgroup of patients with pneu-
monia in both groups is so small that any statistical ana-
lysis is impossible and the power of the sample is quite
small. Future studies are necessary to define the best
treatment of 2009 H1N1 virus pneumonia and the role
of combination antiviral therapy.
The lack of significant differences in the percentages of
patients with hypoxemia between the two groups is prob-
ably due to the proximal number of patients with local
patchy shadowing observed in group B and group A.
(Table 2.)
Obesity is known to be associated with influenza A
(H1N1) viral infection, but in this cohort we observed that
in group B there was a larger number of obese patients
in opposition to group A (88.8% vs. 54.5%) (p = 0.009).
We were unable to explain the reason that the majority of
H1N1 patients were not obese in our study as in previous
reported studies [9,25]. Obesity is not a risk factor for
poor outcomes in patients with seasonal influenza, but
obesity has been suggested as a risk factor for poor out-
comes in patients with 2009 H1N1 influenza infection in
the USA [30].
In our case control study a large number patients suf-
fering from lymphoma were observed, because these
patients received chemotherapy regimen making them
vulnerable to respiratory infections. Patients in group B
had elevated C-reactive protein (mean 12.8 vs. 5.74) and
white blood count WBC in comparison to group A
(mean 10.528 vs. 7.114) suggesting a microbial infection
already upon admission [19-21]. These elevated values
(C-reactive protein and WBC) are known to be asso-
ciated with bacterial infection and early antibiotic treat-
ment prevents progression of the disease as reported in
previous studies [19-21].
Symptoms from oseltamivir were mainly observed in
group A (nausea 4.5% vs. 1.5%, diarrhea 4.5% vs. 1.5%,
vomiting 1.4 vs. 0.5%) probably because of the larger
dose and prolonged treatment with oseltamivir (5.8 vs.
1.93) as previously reported [18,31-33]. However, it was
difficult to distinguish the pharmaceutical side effects of
osetalmivir (tamiflu) from influenza symptoms in
patients receiving antiviral treatment for less than 5
days [23]. Oseltamivir should be given until proof of
negative RT-PCR result, since if a patient is positive, it
prevents progression of the disease as shown in previous
observational studies [17,34,35].
Moreover, mean duration of hospital stay was 5.85 in
g r o u pBv s .6 . 1 1d a y si ng r o u pA ,b e c a u s eo ft h et i m e
needed for normalization of chest radiographs. Never-
theless, there were no significant differences between
the two groups and the days of hospitalization were lim-
ited due to early oseltamivir for group A and antibiotic
treatment for group B as previously explained.
Lastly the mean young age of the patients in both
groups, and the small number of co-morbidities
observed in our sample of patients, possibly were also
responsible for having overall mild clinical course.
In conclusion
All the patients in general, had a mild clinical course
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